Table of Contents
Journal of Cancer Research
Volume 2014 (2014), Article ID 684936, 7 pages
http://dx.doi.org/10.1155/2014/684936
Clinical Study

A Phase IV Clinical Trial of Patients with Solid Tumors Receiving Lenograstim as Primary Prophylaxis for Chemotherapy-Induced Neutropenia, in a Docetaxel-Based Regimen

1Wilgers Oncology Centre, Wilgers Hospital, Denneboom Road, Pretoria, Gauteng 0081, South Africa
2Sanofi South Africa, 2 Bond Street, Grand Central Extension 1, Midrand, Gauteng 1682, South Africa
3GVI Oncology Port Elizabeth, 1 Mangold Street, Newton Park, Port Elizabeth, Eastern Cape 6055, South Africa

Received 8 January 2014; Revised 4 March 2014; Accepted 5 March 2014; Published 6 April 2014

Academic Editor: Norikazu Masuda

Copyright © 2014 Samuel J. Fourie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Samuel J. Fourie, Alicia McMaster, Rashem Mothilal, and Keith I. Maart, “A Phase IV Clinical Trial of Patients with Solid Tumors Receiving Lenograstim as Primary Prophylaxis for Chemotherapy-Induced Neutropenia, in a Docetaxel-Based Regimen,” Journal of Cancer Research, vol. 2014, Article ID 684936, 7 pages, 2014. doi:10.1155/2014/684936